Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Total Liabilities
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has total liabilities worth €47.87 Billion EUR (≈ $55.96 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Guangzhou Baiyunshan Pharmaceutical Hold to evaluate short-term liquidity relative to the company's equity base.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Total Liabilities
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥127.38 Million |
|
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
|
China | CN¥305.98 Million |
|
Tianjin Jinbin Development
SHE:000897
|
China | CN¥1.31 Billion |
|
Jiangsu Jinling Sports Equipment Co Ltd
SHE:300651
|
China | CN¥244.55 Million |
|
Yunnan Yuntou Ecology and Environment Technology Co Ltd
SHE:002200
|
China | CN¥2.94 Billion |
|
Bandwidth Inc
NASDAQ:BAND
|
USA | $640.59 Million |
|
KT Submarine Co. Ltd
KQ:060370
|
Korea | ₩79.71 Billion |
|
Suli Co Ltd
SHG:603585
|
China | CN¥2.18 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GU5 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)
The table below shows the annual total liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €44.43 Billion ≈ $51.94 Billion |
+1.17% |
| 2024-12-31 | €43.91 Billion ≈ $51.34 Billion |
+4.78% |
| 2023-12-31 | €41.91 Billion ≈ $49.00 Billion |
+2.15% |
| 2022-12-31 | €41.03 Billion ≈ $47.97 Billion |
+17.93% |
| 2021-12-31 | €34.79 Billion ≈ $40.67 Billion |
+10.26% |
| 2020-12-31 | €31.55 Billion ≈ $36.89 Billion |
+2.11% |
| 2019-12-31 | €30.90 Billion ≈ $36.13 Billion |
+9.05% |
| 2018-12-31 | €28.34 Billion ≈ $33.13 Billion |
+213.08% |
| 2017-12-31 | €9.05 Billion ≈ $10.58 Billion |
+9.80% |
| 2016-12-31 | €8.24 Billion ≈ $9.64 Billion |
+14.70% |
| 2015-12-31 | €7.19 Billion ≈ $8.40 Billion |
+13.27% |
| 2014-12-31 | €6.34 Billion ≈ $7.42 Billion |
+21.39% |
| 2013-12-31 | €5.23 Billion ≈ $6.11 Billion |
-- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more